Drugs / HMPL-653
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05277454 | Jan 2022 → Jun 2024 | giant cell tumor of soft tissue | Hutchison Medipharma Limited | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-20 | Hutchison Medipharma Limited | HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China hutch-med.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-653 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277454 ↗ |
| Route | Oral | “The participants will receive oral HMPL-653 single-dose evaluation” NCT05277454 ↗ |